

Review

Open Access



# Molecular mechanisms for targeted treatments in fragile X syndrome

Isabel Miranda<sup>1</sup>, Randi Hagerman<sup>1,2</sup>

<sup>1</sup>MIND Institute, University of California Davis Health, Sacramento, CA 95817, USA.

<sup>2</sup>Department of Pediatrics, University of California Davis Health, Sacramento, CA 95817, USA.

**Correspondence to:** Dr. Randi Hagerman, MIND Institute, University California Davis Health, 2825 50th street, Sacramento, CA 95817, USA. E-mail: rjhagerman@ucdavis.edu

**How to cite this article:** Miranda I, Hagerman R. Molecular mechanisms for targeted treatments in fragile X syndrome. *Rare Dis Orphan Drugs J* 2023;2:20. <https://dx.doi.org/10.20517/rdodj.2023.21>

**Received:** 20 Jul 2023 **First Decision:** 14 Aug 2023 **Revised:** 21 Aug 2023 **Accepted:** 30 Aug 2023 **Published:** 7 Oct 2023

**Academic Editor:** Antonio Persico **Copy Editor:** Dan Zhang **Production Editor:** Dan Zhang

## Abstract

Fragile X syndrome (FXS) is caused by a full mutation (> 200 repeats) in the 5'untranslated region of the Fragile X Messenger Ribonucleoprotein 1 gene (*FMR1* gene), which leads to methylation and silencing of expression, generating the total or partial absence of its product, *FMR1* protein (FMRP). When the repetitions are between 55 and 200 cytosine-guanine-guanine (CGG) repeats, it is called a premutation, which is related to a wide spectrum of conditions such as Fragile X-associated tremor ataxia syndrome (FXTAS), fragile X-associated primary ovarian insufficiency (FXPOI), and fragile X-associated neuropsychiatric disorders (FXAND). High levels of *FMR1* mRNA are implicated in premutation pathophysiology, which differs from the deficiency or absence of FMRP in FXS. In recent years, numerous attempts have been made to find treatments that can counteract the effects of the absence of FMRP and improve symptoms associated with the condition such as intellectual disability, anxiety, autism, stereotypies, language delay, and aggressive behavior. Here, we review current treatments in addition to targeted treatments that can reverse some of the neurobiological abnormalities in those with FXS. We also review molecular interventions that will hopefully lead to a promising future for those affected by FXS and their families.

**Keywords:** Rare Disease, FXS, treatment, metformin, sertraline, cannabidiol

## INTRODUCTION

Much progress has been made in the diagnosis and management of FXS since it was first described in 1943



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



and then known as Martin-Bell Syndrome. In a large meta-analysis, the frequency of the full mutation (> 200 CGG repeats) was determined to be 1.4 per 10,000 males and 0.9 per 10,000 females in the general population<sup>[1]</sup>. However, in different parts of the world, the prevalence can be much higher; for instance, in Colombia, there is a village (Ricaurte) where the prevalence of FXS is approximately 1 per 100 because of a founder effect to this region<sup>[2]</sup>.

FXS is the most frequent cause of intellectual disability (ID) and autism of hereditary origin, caused by an expansion of the sequence of CGG trinucleotides repeats to  $\geq 200$  in the region of the promoter of the *FMR1* located on the long arm of the X chromosome at Xq27.3. This full mutation generates silencing through methylation of the gene, leading to the total or partial loss of its product, FMRP. This protein is mainly expressed throughout the brain and in the testes, but also in almost all other tissues and organs<sup>[3]</sup>.

The premutation is 55 to 200 CGG repeats in the promoter region of *FMR1* and it is usually not methylated. Carriers of the premutation usually produce normal levels of FMRP and they are not intellectually impaired; however, they do exhibit elevated levels of *FMR1* mRNA<sup>[4]</sup>. The elevated levels of mRNA lead to toxicity to the neuron and other cells and this causes clinical problems including FXPOI meaning menopause before age 40<sup>[5]</sup>, FXTAS, a neurodegenerative disorder<sup>[6]</sup>, and FXAND affecting approximately 50% of carriers<sup>[7]</sup>.

FMRP binds messenger RNAs, including brain cytoplasmic RNAs and microRNAs, to regulate their transport and translation, interacts with nuclear and cytoplasmic proteins, modulates ionic channels, and is present in synaptic compartments, where it controls the translation of specific mRNAs<sup>[8]</sup>. Structurally, it has three main regions: N-terminal region, central region, and C-terminal region. Each of these regions can bind to RNA molecules<sup>[9]</sup> and FMRP's role in mRNA transport, splicing, and metabolism is important for brain development and aging.

The symptoms and signs related to the total or partial loss of FMRP are variable but usually compromise all areas of development: cognitive, behavioral, sensory, verbal, and motor, which have lifelong consequences. In addition, characteristic physical manifestations such as the elongated face, prominent ears, joint hypermobility, soft skin, and macroorchidism in puberty occur in FXS. The features of FXS require complex management in treatment, which should be addressed by a multidisciplinary team. Here, we present a review of the literature to try to encompass the current optimal therapeutic intervention strategies for these children, adults, and their families affected by fragile X conditions. The literature was selected for controlled medication trials in FXS, the inclusion of systematic reviews in this field of study, key search engines, and follow-up studies. Single-case or abstract conference studies were excluded.

### **Molecular mechanisms of fragile X syndrome**

FMRP is a multi-functional mRNA binding protein that travels to and from the cell nucleus, with a role in the translation, stability, editing, and intracellular transport of hundreds of mRNAs. FMRP also directly interacts with proteins and regulates their function. Additionally, FMRP can regulate RNA synthesis by either controlling the expression of or modulating the activities of transcription factors and chromatin-modifying enzymes, many of which are involved in neurodevelopment and the maintenance of neural connections<sup>[10]</sup>. In the synaptic space, FMRP is associated with the activation of glutamate receptors, both metabotropic (group 1 mGluR 1 and 5) and ionotropic (AMPA and NMDA). Its deficit, therefore, translates into abnormal growth and synaptic plasticity<sup>[11]</sup>. The expression of these receptors is increased in the hippocampus of animals lacking FMRP<sup>[12]</sup>. Despite the successful use of glutamate receptor inhibitors to correct symptoms such as seizures, hyperreactivity, and neural structural changes in knockout (KO) mouse<sup>[12]</sup>, studies in fully-methylated FXS patients with an antagonist of mGluR5 were not successful in

adults or children with FXS<sup>[13,14]</sup>.

The endocannabinoid system is also regulated by FMRP and endogenous cannabinoid ligands such as anandamide (N-arachidonylethanolamine) and 2-arachidonoylglycerol (2-AG), are postulated to play a role in neuronal development and function<sup>[15]</sup>. These ligands bind to cannabinoid receptors type 1 and 2 (CB1 and CB2) and modulate synaptic activity. CB1 is expressed in the brain and is present at lower concentrations in a variety of peripheral tissues and cells. CB2 receptors are expressed primarily in the immune and hematopoietic system, as well as in the brain, pancreas, and bone<sup>[16]</sup>. CB1 can be found at high levels in inhibitory terminals (GABAergic interneurons) and at lower levels in excitatory terminals (glutamatergic) and both play a role in mood and behavior modulation. 2-AG is the most abundant endocannabinoid in the brain and is produced in dendritic spines by activating mGLUR1 receptors. The absence of FMRP in FXS reduces the production of 2-AG, thereby decreasing the activation of CB1 receptors in the central nervous system (CNS)<sup>[17]</sup>. Administration of cannabidiol (CBD) appears to increase 2-AG availability, thereby increasing CB1 receptor activation and attenuating reduced endogenous cannabinoid signaling<sup>[18]</sup>.

In another aspect, FMRP modulates the activation of sodium-potassium channels and calcium channels<sup>[19,20]</sup>, its absence alters the transport and/or translation of specific mRNAs that can influence neuronal excitability.

The GABAergic system is also affected in FXS, leading to an excitatory-inhibitory imbalance, because of reduced expression of subunits at GABA receptors and a reduction in GABAergic interneuronal signaling<sup>[21]</sup>, which play a central role in the presence of autism spectrum disorder (ASD) and FXS<sup>[22]</sup>. FMRP is broadly expressed in GABAergic neuron populations. The GABAergic system normally mediates the inhibitory neurotransmission in the CNS and the lack of FMRP disrupts this system and it was implicated in the pathogenesis of FXS based on studies of GABA-A receptor expression in *Fmr1* KO mice<sup>[22]</sup>. These alterations increase neuronal excitability and further enhance the imbalance of excitation and inhibition. This imbalance leads to enhanced sensitivity to repeated sensory stimuli, a lack of habituation to repetitive stimuli, and subsequent sympathetic hyperactivation, causing anxiety in these patients<sup>[23,24]</sup>.

The normal morphology of dendritic spines also derives from physiological processes modulated in part by FMRP activity. Its absence or decrease leads to a pathological hyperabundance of long, thin immature dendritic protrusions, which result in an abnormal post-synaptic maturation and a failure in the synapse elimination process<sup>[25]</sup>.

Another association studied is the relationship between FMRP and metalloproteinase 9 (MMP9) levels. MMP9 is an enzyme that encodes an endopeptidase important for the maturation of dendritic spines and synaptic formation. MMP9 levels are elevated in FXS because FMRP, which inhibits the translation of the MMP9 mRNA, is missing<sup>[26]</sup>. However, MMP9 levels can be lowered to normal with minocycline treatment<sup>[27,28]</sup>. In fact, in the *Fmr1*-KO mouse, treatment with minocycline improved the maturation of dendritic spines, synapse formation, anxiety levels, and cognitive performance, as well as ultrasonic vocalizations<sup>[29,30]</sup>. In addition, metformin may decrease MMP9 levels in the *Fmr1*-KO mouse<sup>[31]</sup>. Such studies led to the successful trial of minocycline in the treatment of FXS<sup>[28]</sup>.

This knowledge has made it possible to generate therapeutic interventions with multiple medications that can already be applied in clinical practice or are in clinical trials.

### **Coping with FXS and their family inheritance and social environment**

The complexity of the child affected by FXS and the impact on their family and social environment requires that this condition be addressed by a multidisciplinary team guided by a developmental specialist (Pediatrician, Neurologist, or Child Psychiatrist), ideally with experience in FXS.

Treatment will then require pharmacological and non-pharmacological therapy such as speech and language therapy, occupational therapy (OT), physical therapy (PT), counseling, or behavioral interventions such as applied Behavior analysis (ABA) and a healthy lifestyle<sup>[32]</sup>. The inheritance of the fragile X mutation through the pedigree needs to be explained to the family. If a child has the full mutation, the mother is always the carrier because the expansion to  $\geq 200$  CGG repeats only occurs when passed on by the mother. The mother usually has a premutation, but on occasion, she may have a full mutation, so she needs the fragile X DNA test herself. She has approximately a 50% chance of passing on the full mutation to her children because rarely do both X chromosomes carry the mutation. If her premutation is over 90 CGG repeats, then the repeat expansion will expand to a full mutation in the next generation. For premutation carriers with repeats between 55 and 90, there is an increasing risk of going to a full mutation as the repeat number increases. Usually, after every 10 CGG repeats, there is an AGG anchor, and if one or two anchors are present in the mother, this will decrease the risk of expanding to the full mutation up until 90 to 100 repeats when the risk goes to 100% when that mutation is passed on to the next generation<sup>[33,34]</sup>.

If the family has a male premutation carrier, often the father of the mother, then this male will pass on the premutation to all his daughters. Therefore, it is helpful to order fragile X DNA testing for the grandparents because if the grandfather is the carrier, then all of the mother's sisters will be carriers and they will be at high risk of having children with FXS. In addition, premutation carriers need to know the risk of premutation disorders. FXPOI occurs in about 20% of female carriers<sup>[35]</sup>; FXTAS occurs in about 40% of aging male carriers and 16% of aging female carriers<sup>[6]</sup>, and FXAND, which encompasses depression, anxiety, insomnia, chronic pain, and chronic fatigue and social deficits, occurs in up to 50% of carriers, typically in adulthood, but sometimes also in childhood<sup>[7,36,37]</sup>.

### **Cognitive-behavioral challenges and neurological symptoms**

Patients with FXS may present with significant behavioral problems, which usually manifest with greater intensity as they advance in their development, including tactile defensiveness, poor eye contact, hand flapping, hand-biting, clothes chewing, hyperactivity, impulsivity, anxiety, aggressive behavior, and sensory over-reactivity from the second year of life onward. The manifestations of these problems include overfilling or stuffing their mouths with food, and this often translates into obesity. Autism (50%-60% of men, 20% of women)<sup>[38]</sup> or social deficits and attention deficits with/without hyperactivity (80% of boys and 30% of girls) are also more frequent than in the general population<sup>[9]</sup>. Often, in early childhood, sleep difficulties can be seen as well<sup>[39]</sup>. Physical therapy, occupational therapy, speech therapy and ABA<sup>[40]</sup> for ASD are essential within non-pharmacological interventions<sup>[41]</sup>.

ABA is a behavioral intervention commonly used as a therapeutic treatment for ASD. Its premise is to reinforce the positive socially-involved actions of the child. The Early Start Denver Model (ESDM), another model of behavioral intervention, has ABA principles, but focuses on verbal and social skills through interactions with young children ages 1 to 3 in the family environment<sup>[40,42,43]</sup>.

Anxiety is a cardinal symptom in FXS, especially after age 2, and can increase with age and it can also correlate with ASD<sup>[24]</sup>. Low doses of sertraline, a selective serotonin reuptake inhibitor (SSRI), which then prevents the reuptake of serotonin from the synaptic space, has shown significant improvement in anxiety and in visual perception, fine motor coordination, and better T score on the Mullen scale for development

in a controlled trial of young children with FXS ages 2 to 6 years old<sup>[44]</sup>. Those who do not respond to SSRIs, or who exhibit aggressive behaviors (potentially harming others or themselves), or who exhibit violent reactions may respond well to the use of an atypical antipsychotic such as aripiprazole or risperidone, both of which are approved for aggression and irritability in ASD<sup>[45]</sup>. These atypical antipsychotics can block dopamine but also stimulate the serotonin receptors, leading to improvement in aggression and irritability, decreased hyperactivity, and less anxiety in FXS<sup>[46]</sup>. Cognitive behavioral therapy has proven helpful for emotional dysregulation in FXS<sup>[47,48]</sup>.

Other neuropsychiatric manifestations include social or specific phobias, ritualistic and compulsive behaviors, restricted interests, aggressiveness, stereotypies, and self-harming behaviors. Early and intensive psychological and environmental interventions can play a positive role in the management of anxiety, ADHD, social challenges, and depression<sup>[46]</sup>.

Most men with FXS have ID; however, up to 15% (predominantly those with mosaicism) and 70% of women may have an IQ that is normal or close to normal, but still have learning problems and emotional control issues. Cognitive abilities in FXS are known to decline with age in childhood and adolescence<sup>[49]</sup>. Most men with FXS in adulthood have cognitive abilities around an IQ of 40 unless they are mosaic with the partial lack of methylation in the full mutation or a significant percentage of cells with the premutation. The size or methylation mosaicism is associated with a higher IQ than those with a full mutation that is fully methylated because these mosaic individuals are producing a higher level of FMRP<sup>[50,51]</sup>. This is the case of females with a full mutation because their normal X produces FMRP and the amount of FMRP depends on the activation ratio (AR), meaning the percentage of cells with the normal X as the active X usually measured in blood. So, an AR of 0.75 means that 75 percent of her white blood cells have the active X as the normal X, and usually the IQ is relatively high. Approximately 1/3 of girls with the full mutation have an IQ less than 70, 1/3 have an IQ in the borderline range (70 to 85) and 1/3 have an IQ in the normal range (above 85)<sup>[52]</sup>.

By late adulthood, with aging, up to 17% of men with FXS may develop Parkinsonian symptoms, often combined with some additional cognitive impairment<sup>[53]</sup>.

### **Seizures and ASD**

Seizures can also be associated with FXS, usually complex partial, although they can evolve into generalized tonic-clonic seizures or absence seizures<sup>[54]</sup>. Seizures are common in FXS and up to 14% of males and 6% of females have seizures. Seizures often begin between ages 4 and 10 years and data showed that autism was significantly associated with seizures as a co-occurring condition<sup>[55]</sup>. For treatment, Levetiracetam and oxcarbazepine are used as the first line of treatment. Valproate can be another choice and has a mood-stabilizing effect, allowing the improvement of symptoms of aggression or lack of control in some cases<sup>[56]</sup>.

### **Growth, connective tissue, and involvement of other systems**

People affected by FXS may have different associated medical conditions from the spectrum of connective tissue disorders. These include flat feet, scoliosis, joint subluxations, mitral valve prolapse, dilated ureters, and vesicoureteral reflux<sup>[57]</sup>. It is important to rule out aortic root dilation (25%) or mitral valve prolapse (MVP) (3%-20%) if a murmur is heard on auscultation. Another possible finding of the cardiovascular system is the decrease in parasympathetic vagal tone, especially in children who are hyperaroused. Hypertension is common in obese patients and in adulthood, and this may be related to enhanced anxiety. If hypertension or a murmur is heard, then referral to cardiology, where an evaluation including an ultrasound, is carried out that can document MVP or other cardiac problems. It is worth mentioning that carriers of the premutation may also present with cardiovascular symptoms such as arrhythmias and

dysautonomia<sup>[58]</sup>.

Obesity occurs in about 35% of those with FXS before they reach adolescence, especially in those with hyperphagia and a lack of satiation after meals<sup>[59]</sup>. In about 10%, these behavioral features can lead to a Prader-Willi-like phenotype with severe obesity and this has a biomarker of low cytoplasmic FMRP interacting protein (CYFIP) levels reported by Nowicki *et al.*<sup>[60]</sup>. These children present with severe hyperphagia and early obesity (6-9 years) and typically have small genitalia and delayed puberty. Knowing the increased risk of obesity, it is important to encourage regular physical exercise, ideally daily, and to promote a healthy diet by avoiding foods rich in saturated fats and sugar. The therapy is complex and requires multidisciplinary support from experts in the field for behavioral interventions and medications.

Annual pediatric health checkups should include otoscopy and appropriate treatment of otitis media which is often recurrent in the first years of life. It is recommended to have early and frequent hearing screens, especially if there is a history of recurrent ear infections, to avoid a greater impact on language acquisition<sup>[61]</sup>. Children with FXS may have difficulty communicating discomfort or pain, so in the face of otitis, they may hit their head, and this may be the only outward symptom of infection. Recurrent otitis media infections often require insertion of Pressure Equalizer tubes (PE tubes) and sometimes adenoidectomy and/or tonsillectomy.

An evaluation by an ophthalmologist is recommended between 3 and 4 years of age to evaluate and correct visual acuity problems (astigmatism, hypermetropia, strabismus). If strabismus is noted (occurs in about 20% of FXS patients), it should be evaluated as early as possible to avoid the development of amblyopia. Nystagmus, convergence insufficiency, and eyelid ptosis have also been reported, but are less common<sup>[54,56]</sup>.

In the gastrointestinal sphere, loose stools are usually the norm in FXS, but in some rare cases, constipation may occur. Toilet training is typically delayed because of sensory issues and cognitive deficits, but the biggest problem is training them to wipe themselves successfully after a bowel movement. OT therapy is often helpful in addressing this problem. Gastro-esophageal reflux is more common in infants with FXS (leading to frequent emesis) than in the general population. These symptoms should be screened carefully, diagnostic studies performed, and treatment implemented if appropriate<sup>[62]</sup>.

### Therapies

Almost all young children with FXS need early intervention beginning by 2 years old or earlier and they benefit from speech and language therapy, OT, and PT<sup>[41]</sup>. In general, motor involvement is one of the first findings noticed in early development. Most children affected by FXS are hypotonic, which will translate into delayed onset of motor milestones such as the ability to sit without support and the onset of walking. In the neonatal and infant period, they may have difficulties in sucking and frequent regurgitation. Physical therapy and occupational therapy are important for supporting motor development.

They usually have poor language development and some children, especially boys and those with comorbidity with autism, may be completely nonverbal for several years. Speech problems of males with FXS include variability in rate and stuttering-like repetition of sounds. Also notable among the features displayed by males is perseveration on a word, phrase, or topic in conversation, which is probably related to the hyperarousal and frontal-lobe-executive function deficits<sup>[63]</sup>. Speech therapy is incorporated as a central element of intervention in the first years of life. PROMPT therapy can be helpful for the nonverbal child at 2 years old, and this therapy involves tactile stimulation to the mouth to facilitate the expression of language<sup>[64]</sup>. For those who continue to be nonverbal, sign language can be a bridge to oral communication,

in addition to the use of augmentative and assistive communication devices and they are usually initiated by the speech and language therapist<sup>[41]</sup>.

School integration programs with special education are necessary for these children when accessing the school system. Resources or plans for these children can be found on online portals such as [www.fragileX.org](http://www.fragileX.org); [www.fragilex.org.uk](http://www.fragilex.org.uk); or [www.fragilex.org.au](http://www.fragilex.org.au).

## PSYCHOPHARMACOLOGY

### Attention deficit hyperactivity disorder and treatment

As previously noted, ADHD can be diagnosed in approximately 80% of boys and about 30% of girls with FXS. However, the usual treatment of ADHD with stimulants can cause irritability when given to children less than 5 years old with FXS<sup>[46]</sup>. For those who are 5, and older stimulants are usually tolerated well, especially the long-acting preparations when once-a-day dosing in the morning leads to a stable level in blood during the day. These First-Line medications improve norepinephrine and dopamine levels at the synapse in the prefrontal cortex, which play a role in improving motivation, attention, and impulse control. For children under 5 years of age with excessive hyperactivity, guanfacine or clonidine may be considered. Clonidine is especially helpful for sleep problems when given at bedtime because of its sedative effect. Guanfacine has an overall calming effect, which calms down hyperactivity and hyperarousal when given in the morning and in the afternoon after school. In some countries, such as Italy, stimulants are not authorized, so an alternative for attention deficit symptoms is L-acetylcarnitine or valproic acid<sup>[65,66]</sup>.

In general, the use of stimulants such as methylphenidate or mixed amphetamine salts should start at a low dose and then follow-up visits should follow weight and vitals, particularly blood pressure, since both can be affected in children with FXS. If weight loss occurs, then the dose should be lowered or even discontinued on weekends, and increased food intake can occur before bed when the medication has worn off. In general, the stimulants are well tolerated; however, it is important to note that at higher doses, they can have a quieting effect on language. Therefore, it is advisable to avoid administering high doses<sup>[46]</sup>.

### Sleep

At each medical visit, it is suggested to check sleep quality and time for sleep because these parameters influence the development, learning, and functioning of any child, including those affected by FXS. Children under 3 years old with FXS often have wakefulness at night and they may get up and search for parents. Seizures can also occur at night in about 15% of young children with FXS<sup>[67]</sup>. Sleep apnea also can occur in young children, especially if there is a history of snoring and obstruction heard at night by the parents. Referral to an Ear Nose and Throat (ENT) specialist and a sleep study can clarify if sleep apnea is occurring, and an adenoidectomy/tonsillectomy typically eliminates sleep apnea in a young child with FXS.

The use of melatonin is the most effective medication as a primary treatment of sleep wakening in young children with FXS<sup>[68]</sup>. Not only does melatonin play a role as a sleep inducer, but it also has antioxidant properties and it facilitates neuronal plasticity<sup>[69]</sup>. Melatonin should not be given in the daytime because it can cause drowsiness during the day.

### Targeted treatments for fragile X syndrome

Most of these treatments, promoted in the last decade, are supported by research conducted in FXS animal models with a KO of *FMR1* and the neurobiological effect that this entails. The current objective is to be able to, on the one hand, reactivate the damaged gene and, on the other hand, replace the effects of the absence of the FMRP protein.

Early attempts used negative modulators of mGluR5 receptors (mGluR antagonists) since this pathway is upregulated in FXS. Favorable results have been shown in animal studies using these antagonists, but in humans, the results have been negative<sup>[70-72]</sup>. Even the use of the mGluR5 antagonist AFQ056 in young children with FXS combined with parent-implemented language intervention (PILI) has not demonstrated efficacy over a prolonged period of time in a controlled trial<sup>[73]</sup>.

GABA-A and GABA-B receptor agonists can reverse some of the symptoms in the animal model of FXS and would be useful under the theory that GABA pathways are also affected in individuals with FXS and that problems such as seizures and sleep disturbances are associated with this pathway. FMRP acts as a modulator of these GABA receptors. Clinical studies with Arbaclofen (selective GABA-B agonist) showed improvement in the symptoms of social isolation and behavioral problems reported by parents of patients with FXS, compared to placebo<sup>[74]</sup>; however, in phase III studies with adolescents and adults, Arbaclofen did not show improvement<sup>[75]</sup>. In the group of 5 to 11 years, an observable improvement was maintained in the application of the ABC FX test (Aberrant Behavior Checklist-community Edition, factored for FXS)<sup>[76]</sup>, so arbaclofen will be studied again in FXS by the Allos company. Acamprosate (positive allosteric modulator of the GABA-A receptor)<sup>[77]</sup> and metadoxine (an indirect GABA activator) have been tested in small placebo-control groups of FXS individuals. Metadoxine has shown improvement when evaluated with the Vineland Daily Living Skills subscale and in the computerized cognitive Test of Attentional Performance for Children (KiTAP) test (executive function tasks) compared with individuals who received placebo<sup>[78]</sup>. Ganaxolone has shown improvement in anxious symptoms in a specific subgroup of participants with greater severity of anxiety, but it was not efficacious for the overall group of FXS<sup>[79]</sup>. A placebo-free study of 3 doses of Gaboxadol, a GABA-a receptor agonist, was carried out in 28 adolescent and adult males with FXS, and there was a 60% response rate, suggesting that further studies are warranted in a controlled trial with placebo<sup>[80]</sup>.

Minocycline, an antibiotic of the tetracycline family acts by lowering matrix metalloproteinase-9 (MMP9) expression and activity levels, which, in turn, can improve the maturity and strength of synaptic connections in the *Fmr1*-KO mouse<sup>[29]</sup>. One controlled study demonstrated significant improvement in behavior in children with FXS measured with the Clinical Global Impression Scale and the Visual Analogue Scale<sup>[28]</sup>. Thus, this medication is used in clinics to help with behavioral problems, anxiety, and attention in children with FXS at times. Other benefits of minocycline are its antioxidant power and anti-apoptotic effects. Unfortunately, it has certain side effects such as the permanent darkening of the teeth (when used in children under 8 years) and also, sometimes increasing the levels of antinuclear antibodies (ANA), which can trigger a Lupus-Like syndrome with rash or inflammation of joints (reversible when treatment is stopped). Therefore, if minocycline is used in treatment, then the ANA should be tested every 6 months or once a year if the patient is stable without side effects.

Another drug is trofinetide, a terminal analog of the tripeptide of the insulin-like growth factor that can decrease abnormal ERK and AKT activity, normalizing the phenotype in the KO mouse. An exploratory, phase 2, multicenter, double-blind, placebo-controlled, parallel-group study of the safety and tolerability of orally administered trofinetide to adolescent and adult males with FXS was performed. Trofinetide was well tolerated and showed a consistent signal of efficacy at the higher dose observed by caregiver and clinician assessments despite the relatively short duration of treatment<sup>[81]</sup>.

Lovastatin, a statin, is another drug under study, which, in *in vitro* studies, has corrected excessive protein synthesis at the level of the hippocampus of the *Fmr1*-KO mouse and, when administered orally or injected, was able to inhibit the expression of audiogenic-induced seizures. Being a drug already FDA-approved and



widely used in adults and children for the management of hypercholesterolemia, it was exciting to continue testing it as a specific therapeutic alternative for FXS. Unfortunately, a controlled trial of lovastatin combined with an open-label treatment of a PILI in youth with FXS did not show greater benefit than the use of PILI alone<sup>[82]</sup>.

### *Metformin*

Another specific targeted treatment for FXS is metformin, a first-line medication in the treatment of type 2 diabetes that acts by decreasing the hepatic production of glucose, decreasing absorption of glucose at the intestinal level and increasing insulin sensitivity, which leads to lower plasma glucose levels. Metformin in the *fmr1*-KO mouse has been shown to reduce ERK signaling and decrease levels of phosphorylated EIF4E and MMP9<sup>[31]</sup>. Metformin can also alleviate features of FXS in the *Drosophila* model of FXS by lowering the up-regulation of the mTOR pathway that is seen in FXS<sup>[83]</sup>. Metformin is also known to reduce obesity, especially in children or adults with ASD who have gained weight because of antipsychotic use<sup>[84]</sup>. Initially, metformin was tried in patients with FXS and the Prader-Willi-like phenotype with obesity and it helped to reduce the obesity<sup>[85]</sup>. In addition, it was tried in FXS without obesity and the families saw an improvement in language and conversational abilities. In young children 3 to 7 years, an open-label trial of metformin improved both behavior and cognitive abilities on the Mullen Scales of Early Learning compared to the early development of FXS documented in the literature<sup>[86]</sup>. Subsequent cases of FXS have demonstrated improvement in IQ in two adult males treated clinically with metformin<sup>[87]</sup> and another case where macroorchidism did not develop when metformin was started before puberty<sup>[88]</sup>. Currently, a controlled trial of metformin treatment over 4 months for individuals with FXS from ages 8 to 45 is taking place at three centers, including the MIND Institute at UC Davis and at the University of Edmonton in Canada and St Justine Hospital in Montreal. Results should be available in early 2024. Because of clinical reports demonstrating its benefits, metformin is often used clinically and we all await the results of the controlled trial.

### *Cannabidiol*

CBD has an antioxidant, anti-inflammatory, and neuroprotective effect, so it could be useful in patients with neurodevelopmental disorders where neuro-inflammation and immune dysregulation would play a role in pathogenesis, such as in ASD<sup>[89]</sup>. Moreover, its anxiolytic effect, via GABA enhancement and activation of the cannabinoid type 1 receptor, has been shown to improve anxious symptoms in patients with autism<sup>[90]</sup>. Its positive medicinal effects include the control of seizures in children with Lennox Gastaut syndrome and Dravet syndrome<sup>[91]</sup>. Moreover, parents of children with refractory epilepsy reported improvement in attention and behavior when treated with CBD<sup>[92]</sup>.

Zynerba has manufactured CBD that is free of THC and has carried out a twelve-week controlled trial of this topical ointment in children with FXS at a dose of 250 mg to 500 mg (weight dependent) rubbed on the shoulder skin twice a day. This topical preparation of CBD demonstrated significant benefit for the primary outcome measure of Social Avoidance, a subtest of the Aberrant Behavioral Checklist for Fragile X (ABC FX) in those children who had > 90% methylation<sup>[93]</sup>. However, because it did not demonstrate efficacy for those with FXS who were mosaic, the FDA asked Zynerba to carry out a second treatment study where the molecular subgroups were further studied and this trial, called RECONNECT, is currently ongoing at multiple international sites. CBD not only improved social avoidance but also benefited anxiety and outburst behavior so that the Quality of Life was improved for the families, and they found that they could go on outings with their children without severe behavioral manifestations. However, this medication is not available from *marijuana* stores presently, and the closest alternative is hemp-derived CBD, which has a very low level of THC (< 1%) and is typically available in tinctures or gummies<sup>[94]</sup>. CBD may also be helpful

for premutation carriers who often have symptoms of insomnia, anxiety, and chronic pain associated with FXAND<sup>[36]</sup>.

#### *Phosphodiesterase 4D inhibitor: BPN14770*

Perhaps the most exciting treatment study in FXS was the use of BPN14770, which inhibits the breakdown of cAMP because cAMP is deficient in FXS. The use of this inhibitor raised cAMP levels and improved cognition substantially in a controlled trial. Thirty adults with FXS were treated for 14 weeks with either a placebo or BPN14770 at a dose of 25 mg twice a day<sup>[95]</sup>. The cognitive outcome measure was the NIH toolbox, which had been modified by Dr. David Hessel and his team to be useful in individuals with ID<sup>[96]</sup>. They found that multiple measures on the NIH toolbox improved in those treated with BPN14770 compared to placebo including Oral Reading Recognition, Picture Vocabulary, and the Cognition Crystallized Composite Score in addition to the parents' documentation of improvements in language and daily functioning on the Visual Analogue Scale. Such significant improvements in cognition in adults with FXS have never been seen before, so this medication has brought hope to the fragile X field that cognitive deficits can be improved even in adulthood. Currently, phase III controlled trials of BPN14770 are being carried out in adolescents and adults with FXS at multiple centers, and by the end of 2023, such trials will likely take place in children with FXS.

#### *Gene therapy*

Advances in DNA technology have been used to correct CGG expansions with pluripotent cells. Eventually, in the future, these cells can enter into the CNS of patients affected with FXS to correct the expansion. Recently, an approach to correct the genetic defect in FXS was described via recruitment of endogenous repair mechanisms that then drive excision of the long CGG repeat. FMRP restoration through *de novo* transcription, can be induced by demethylation and resolution of the aberrant R-loops in the *FMR1* gene in cellular models, identifying a potential method of treating FXS in the future<sup>[97]</sup>. Another study that sought to deliver ASOs into the brain of FXTAS affected mouse models showed reduced inclusion formation, improved motor response, and correction of gene expression profiling<sup>[98]</sup>. These studies raised hope for the development of future curative treatments, and it is exciting to witness the development of therapeutic alternatives that until recently were unthinkable.

## **CONCLUSION**

Animal models and advances in understanding the molecular dysregulation present in FXS have led to several targeted treatments described here that have improved the lives of many patients with FXS. Support and intervention for patients should extend to their family and environment. The quality of life of each of these individuals will be affected differently depending on the level of ID, behavioral challenges, the presence of aggressiveness or disruptive behaviors, and the comorbidity present in both the patient and their caregivers. Parents can be affected emotionally, having to assume the responsibility of ensuring the health of the child, and battling chronic stress or major depression, especially those caregivers who have the premutation with FXAND and/or FXPOI. Family support is a fundamental pillar in therapeutic approaches. PILI is an alternative that strengthens communication channels between parents and children. It is recommended to have counseling, parent group support, educational alternatives, and psychological and/or psychiatric- intervention when necessary.

## **DECLARATIONS**

### **Acknowledgments**

We acknowledge the patients and their families who have been our power inspiration to work in this field and our own families who have provided the encouragement to keep moving forward.

### Authors' contributions

Wrote the first draft of this paper: Miranda I

Added additional information and edits: Hagerman R

### Availability of data and materials

Not applicable.

### Financial support and sponsorship

Support for this research comes from the Azrieli Foundation, private donors, and the Intellectual and Developmental Research Center at the MIND Institute NICHD (grant P50 HD103526).

### Conflicts of interest

Dr Hagerman has been funded by Zynerba to carry out a controlled trial of CBD in individuals with Fragile X Syndrome. The Azrieli Foundation has funded Dr Hagerman to carry out a controlled trial of metformin in individuals with Fragile X Syndrome. Dr Miranda has no conflicts pertinent to this paper.

### Ethical approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

### Copyright

© The Author(s) 2023.

## REFERENCES

1. Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, Leal J. Epidemiology of fragile X syndrome: a systematic review and meta-analysis. *Am J Med Genet A* 2014;164A:1648-58. [DOI](#) [PubMed](#)
2. Saldarriaga W, Forero-Forero JV, González-Teshima LY, et al. Genetic cluster of fragile X syndrome in a Colombian district. *J Hum Genet* 2018;63:509-16. [DOI](#)
3. Bakker CE, de Diego Otero Y, Bontekoe C, et al. Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse. *Exp Cell Res* 2000;258:162-70. [DOI](#)
4. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. *Am J Hum Genet* 2000;66:6-15. [DOI](#) [PubMed](#) [PMC](#)
5. Sherman SL. Premature ovarian failure in the fragile X syndrome. *Am J Med Genet* 2000;97:189-94. [DOI](#) [PubMed](#)
6. Hagerman RJ, Hagerman P. Fragile X-associated tremor/ataxia syndrome-features, mechanisms and management. *Nat Rev Neurol* 2016;12:403-12. [DOI](#) [PubMed](#)
7. Hagerman RJ, Protic D, Rajaratnam A, Salcedo-Arellano MJ, Aydin EY, Schneider A. Fragile X-associated neuropsychiatric disorders (FXAND). *Front Psychiatry* 2018;9:564. [DOI](#) [PubMed](#) [PMC](#)
8. Salcedo-Arellano MJ, Hagerman RJ, Martínez-Cerdeño V. Fragile X syndrome: clinical presentation, pathology and treatment. *Gac Med Mex* 2020;156:60-6. [DOI](#) [PubMed](#)
9. Hagerman RJ, Berry-Kravis E, Hazlett HC, et al. Fragile X syndrome. *Nat Rev Dis Primers* 2017;3:17065. [DOI](#)
10. Richter JD, Zhao X. The molecular biology of FMRP: new insights into fragile X syndrome. *Nat Rev Neurosci* 2021;22:209-22. [DOI](#) [PubMed](#) [PMC](#)
11. Bagni C, Oostra BA. Fragile X syndrome: from protein function to therapy. *Am J Med Genet A* 2013;161A:2809-21. [DOI](#) [PubMed](#)
12. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. *Proc Natl Acad Sci U S A* 2002;99:7746-50. [DOI](#) [PubMed](#) [PMC](#)
13. Berry-Kravis E, Des Portes V, Hagerman R, et al. Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. *Sci Transl Med* 2016;8:321ra5. [DOI](#)
14. Youssef EA, Berry-Kravis E, Czech C, et al; FragXis Study Group. Effect of the mGluR5-NAM basimglurant on behavior in adolescents and adults with fragile X syndrome in a randomized, double-blind, placebo-controlled trial: fragXis phase 2 results. *Neuropsychopharmacology* 2018;43:503-12. [DOI](#) [PubMed](#) [PMC](#)
15. Katona I, Freund TF. Multiple functions of endocannabinoid signaling in the brain. *Annu Rev Neurosci* 2012;35:529-58. [DOI](#)

[PubMed PMC](#)

16. Palumbo JM, Thomas BF, Budimirovic D, et al. Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment. *J Neurodev Disord* 2023;15:1. [DOI PubMed PMC](#)
17. Jung KM, Sepers M, Henstridge CM, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. *Nat Commun* 2012;3:1080. [DOI PubMed PMC](#)
18. Heussler H, Cohen J, Silove N, et al. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. *J Neurodev Disord* 2019;11:16. [DOI PubMed PMC](#)
19. Ferron L, Nieto-Rostro M, Cassidy JS, Dolphin AC. Fragile X mental retardation protein controls synaptic vesicle exocytosis by modulating N-type calcium channel density. *Nat Commun* 2014;5:3628. [DOI PubMed PMC](#)
20. Bausch AE, Ehinger R, Straubinger J, Zerfass P, Nann Y, Lukowski R. Loss of sodium-activated potassium channel slack and FMRP differentially affect social behavior in mice. *Neuroscience* 2018;384:361-74. [DOI PubMed](#)
21. Tempio A, Bouksibat A, Bardoni B, Delhaye S. Fragile X syndrome as an interneuronopathy: a lesson for future studies and treatments. *Front Neurosci* 2023;17:1171895. [DOI PubMed PMC](#)
22. Paluszkiwicz SM, Olmos-Serrano JL, Corbin JG, Huntsman MM. Impaired inhibitory control of cortical synchronization in fragile X syndrome. *J Neurophysiol* 2011;106:2264-72. [DOI PubMed PMC](#)
23. Miller L, Mcintosh D, Mcgrath J, et al. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. *Am J Med Genet* 1999;83:268-79. [DOI](#)
24. Cordeiro L, Ballinger E, Hagerman R, Hessel D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. *J Neurodev Disord* 2011;3:57-67. [DOI PubMed PMC](#)
25. Khayachi A, Gwizdek C, Poupon G, et al. Sumoylation regulates FMRP-mediated dendritic spine elimination and maturation. *Nat Commun* 2018;9:757. [DOI PubMed PMC](#)
26. Janusz A, Milek J, Perycz M, et al. The fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses. *J Neurosci* 2013;33:18234-41. [DOI PubMed PMC](#)
27. Dziembowska K, Pretto DI, Janusz A, et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. *Am J Med Genet A* 2013;161A:1897-903. [DOI](#)
28. Leigh MJ, Nguyen DV, Mu Y, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. *J Dev Behav Pediatr* 2013;34:147-55. [DOI PubMed PMC](#)
29. Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. *J Med Genet* 2009;46:94-102. [DOI](#)
30. Dansie LE, Phommahaxay K, Okusanya AG, et al. Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice. *Neuroscience* 2013;246:186-98. [DOI PubMed PMC](#)
31. Gantois I, Khoutorsky A, Popic J, et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. *Nat Med* 2017;23:674-7. [DOI](#)
32. Protic DD, Aishworiya R, Salcedo-Arellano MJ, et al. Fragile X syndrome: from molecular aspect to clinical treatment. *Int J Mol Sci* 2022;23:1935. [DOI PubMed PMC](#)
33. Yrigollen CM, Martorell L, Durbin-Johnson B, et al. AGG interruptions and maternal age affect FMR1 CGG repeat allele stability during transmission. *J Neurodev Disord* 2014;6:24. [DOI PubMed PMC](#)
34. Nolin SL, Glicksman A, Ersalesi N, et al. Fragile X full mutation expansions are inhibited by one or more AGG interruptions in premutation carriers. *Genet Med* 2015;17:358-64. [DOI PubMed](#)
35. Sullivan AK, Marcus M, Epstein MP, et al. Association of FMR1 repeat size with ovarian dysfunction. *Hum Reprod* 2005;20:402-12. [DOI](#)
36. Rajaratnam A, Shergill J, Salcedo-Arellano M, Saldarriaga W, Duan X, Hagerman R. Fragile X syndrome and fragile X-associated disorders. *F1000Res* 2017;6:2112. [DOI PubMed PMC](#)
37. Aishworiya R, Hwang YH, Santos E, et al. Clinical implications of somatic allele expansion in female FMR1 premutation carriers. *Sci Rep* 2023;13:7050. [DOI PubMed PMC](#)
38. Harris SW, Hessel D, Goodlin-Jones B, et al. Autism profiles of males with fragile X syndrome. *Am J Ment Retard* 2008;113:427-38. [DOI PubMed PMC](#)
39. Budimirovic DB, Protic DD, Delahunty CM, et al; FORWARD Consortium. Sleep problems in fragile X syndrome: cross-sectional analysis of a large clinic-based cohort. *Am J Med Genet A* 2022;188:1029-39. [DOI](#)
40. Vismara LA, McCormick CEB, Shields R, Hessel D. Extending the parent-delivered early start denver model to young children with fragile X syndrome. *J Autism Dev Disord* 2019;49:1250-66. [DOI](#)
41. Chitwood KL, Hess LG, Diez-Juan M, and Braden ML. Chapter 10: academic intervention and therapies for children with FXS. Fragile X syndrome and premutation disorders: new developments and treatments. London: Mac Keith Press; 2020. Available from: <https://www.mackeith.co.uk/product/fragile-x-syndrome-and-premutation-disorders-chapter-10-academic-intervention-and-therapies-for-children-with-fxs/> [Last accessed on 6 Sep 2023].
42. Dawson G, Rogers S, Munson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: the early start denver model. *Pediatrics* 2010;125:e17-23. [DOI PubMed PMC](#)
43. Vismara LA, Rogers SJ. Behavioral treatments in autism spectrum disorder: what do we know? *Annu Rev Clin Psychol* 2010;6:447-68. [DOI PubMed](#)

44. Greiss Hess L, Fitzpatrick SE, Nguyen DV, et al. A randomized, double-blind, placebo-controlled trial of low-dose sertraline in young children with fragile X syndrome. *J Dev Behav Pediatr* 2016;37:619-28. DOI PubMed PMC
45. Eckert EM, Dominick KC, Pedapati EV, et al. Pharmacologic interventions for irritability, aggression, agitation and self-injurious behavior in fragile X syndrome: an initial cross-sectional analysis. *J Autism Dev Disord* 2019;49:4595-602. DOI PubMed PMC
46. Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. *Pediatrics* 2009;123:378-90. DOI PubMed PMC
47. Moskowitz LJ, Jones EA. Uncovering the evidence for behavioral interventions with individuals with fragile X syndrome: a systematic review. *Res Dev Disabil* 2015;38:223-41. DOI PubMed
48. Amor DJ. Fragile X Syndrome and Premutation Disorders: New Developments and Treatments Edited by Randi J, Hagerman and Paul J, Hagerman. London: Mac Keith Press, 2020. £75.00 (Hardback), pp 176. ISBN: 9781911612377. *Develop Med Child Neuro* 2021;63:119. DOI
49. Schneider A, Ligsay A, Hagerman RJ. Fragile X syndrome: an aging perspective. *Dev Disabil Res Rev* 2013;18:68-74. DOI PubMed PMC
50. Tassone F, Hagerman RJ, Ikle DN, et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. *Am J Med Genet* 1999;84:250-61. DOI
51. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. *Ment Retard Dev Disabil Res Rev* 2004;10:31-41. DOI PubMed
52. de Vries BB, Wiegers AM, Smits AP, et al. Mental status of females with an FMR1 gene full mutation. *Am J Hum Genet* 1996;58:1025-32. PubMed PMC
53. Utari A, Adams E, Berry-Kravis E, et al. Aging in fragile X syndrome. *J Neurodev Disord* 2010;2:70-6. DOI PubMed PMC
54. Kidd SA, Lachiewicz A, Barbooth D, et al. Fragile X syndrome: a review of associated medical problems. *Pediatrics* 2014;134:995-1005. DOI
55. Berry-Kravis E, Raspa M, Loggin-Hester L, Bishop E, Holiday D, Bailey DB. Seizures in fragile X syndrome: characteristics and comorbid diagnoses. *Am J Intellect Dev Disabil* 2010;115:461-72. DOI PubMed
56. Hagerman RJ, Protic D, Berry-Kravis EM. Chapter 5: medical, psychopharmacological, and targeted treatment for FXS. London: Mac Keith; 2020. Available from: <https://www.mackeith.co.uk/product/fragile-x-syndrome-and-premutation-disorders-chapter-5-medical-psychopharmacological-and-targeted-treatment-for-fxs/> [Last accessed on 6 Sep 2023].
57. Ramírez-Cheyne JA, Duque GA, Ayala-Zapata S, et al. Fragile X syndrome and connective tissue dysregulation. *Clin Genet* 2019;95:262-7. DOI
58. Tassanakijpanich N, Cohen J, Cohen R, Srivatsa UN, Hagerman RJ. Cardiovascular problems in the fragile X premutation. *Front Genet* 2020;11:586910. DOI PubMed PMC
59. McLennan Y, Polussa J, Tassone F, Hagerman R. Fragile X syndrome. *Curr Genomics* 2011;12:216-24. DOI
60. Nowicki ST, Tassone F, Ono MY, et al. The Prader-willi phenotype of fragile X syndrome. *J Dev Behav Pediatr* 2007;28:133-8. DOI
61. Badran HS, Abulnaser KM, Abd El Hameed Nasser S. Effect of recurrent otitis media on language profile in children with fragile X syndrome. *Clin Med Insights Ear Nose Throat* 2013;6:1-7. DOI PubMed PMC
62. Berry-kravis E, Grossman AW, Crnic LS, Greenough WT. Understanding fragile X syndrome. *Current Paediatrics* 2002;12:316-24. DOI
63. Abbeduto L, Hagerman RJ. Language and communication in fragile X syndrome. *Ment Retard Dev Disabil Res Rev* 1997;3:313-22. DOI
64. Grigos MI, Hayden D, Eigen J. Perceptual and articulatory changes in speech production following PROMPT treatment. *J Med Speech Lang Pathol* 2010;18:46-53. PubMed PMC
65. Torrioli M, Vernacotola S, Setini C, et al. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. *Am J Med Genet A* 2010;152A:1420-7. DOI
66. Frigerio A, Montali L, Fine M. Attention deficit/hyperactivity disorder blame game: a study on the positioning of professionals, teachers and parents. *Health* 2013;17:584-604. DOI
67. Berry-kravis E. Epilepsy in fragile X syndrome. *Dev Med Child Neurol* 2002;44:724-8. DOI
68. Wirojanan J, Jacquemont S, Diaz R, et al. The Efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. *J Clin Sleep Med* 2009;5:145-50. DOI PubMed PMC
69. Biggio G, Biggio F, Talani G, et al. Melatonin: from neurobiology to treatment. *Brain Sci* 2021;11:1121. DOI PubMed PMC
70. Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. *Sci Transl Med* 2011;3:64ra1. DOI
71. Levenga J, Hayashi S, de Vrij FM, et al. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. *Neurobiol Dis* 2011;42:311-7. DOI
72. Mullard A. Fragile X disappointments upset autism ambitions. *Nat Rev Drug Discov* 2015;14:151-3. DOI PubMed
73. Berry-Kravis E. Disease-targeted treatment translation in fragile X syndrome as a model for neurodevelopmental disorders. *J Child Neurol* 2022;37:797-812. DOI
74. Berry-Kravis EM, Hessel D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. *Sci Transl Med* 2012;4:152ra127. DOI
75. Berry-Kravis E, Hagerman R, Visootsak J, et al. Arbaclofen in fragile X syndrome: results of phase 3 trials. *J Neurodev Disord*

- 2017;9:3. DOI PubMed PMC
76. Sansone SM, Widaman KF, Hall SS, et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. *J Autism Dev Disord* 2012;42:1377-92. DOI PubMed PMC
  77. Erickson CA, Wink LK, Ray B, et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. *Psychopharmacology (Berl)* 2013;228:75-84. DOI
  78. Erickson CA, Davenport MH, Schaefer TL, et al. Fragile X targeted pharmacotherapy: lessons learned and future directions. *J Neurodev Disord* 2017;9:7. DOI PubMed PMC
  79. Ligsay A, Van Dijck A, Nguyen DV, et al. A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. *J Neurodev Disord* 2017;9:26. DOI PubMed PMC
  80. Budimirovic DB, Dominick KC, Gabis LV, et al. Gaboxadol in fragile X syndrome: a 12-week randomized, double-blind, parallel-group, phase 2a study. *Front Pharmacol* 2021;12:757825. DOI PubMed PMC
  81. Berry-Kravis E, Horrigan JP, Tartaglia N, et al; FXS-001 Investigators. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of fragile X syndrome. *Pediatr Neurol* 2020;110:30-41. DOI
  82. Thurman AJ, Potter LA, Kim K, et al. Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome. *J Neurodev Disord* 2020;12:12. DOI PubMed PMC
  83. Monyak RE, Emerson D, Schoenfeld BP, et al. Insulin signaling misregulation underlies circadian and cognitive deficits in a *Drosophila* fragile X model. *Mol Psychiatry* 2017;22:1140-8. DOI PubMed PMC
  84. Wang M, Tong JH, Zhu G, Liang GM, Yan HF, Wang XZ. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. *Schizophr Res* 2012;138:54-7. DOI
  85. Dy ABC, Tassone F, Eldeeb M, Salcedo-Arellano MJ, Tartaglia N, Hagerman R. Metformin as targeted treatment in fragile X syndrome. *Clin Genet* 2018;93:216-22. DOI PubMed PMC
  86. Biag HMB, Potter LA, Wilkins V, et al. Metformin treatment in young children with fragile X syndrome. *Mol Genet Genomic Med* 2019;7:e956. DOI PubMed PMC
  87. Protic D, Aydin EY, Tassone F, Tan MM, Hagerman RJ, Schneider A. Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases. *Mol Genet Genomic Med* 2019;7:e00745. DOI PubMed PMC
  88. Protic D, Kaluzhny P, Tassone F, Hagerman R. Prepubertal metformin treatment in fragile X syndrome alleviated macroorchidism: a case study. Available from: <https://www.semanticscholar.org/paper/Prepubertal-Metformin-Treatment-in-Fragile-X-A-Case-Protic-Kaluzhny/bc72f48893f277b9dc271413fe51e099935fbfb6> [Last accessed on 1 Sep 2023].
  89. Carbone E, Manduca A, Cacchione C, Vicari S, Trezza V. Healing autism spectrum disorder with cannabinoids: a neuroinflammatory story. *Neurosci Biobehav Rev* 2021;121:128-43. DOI PubMed
  90. da Silva EA, Medeiros WMB, Santos JPMD, et al. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind and placebo-controlled clinical trial. *Trends Psychiatr Psy* 2022:ahead of print. DOI
  91. Thiele EA, Marsh ED, French JA, et al; GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2018;391:1085-96. DOI
  92. Metternich B, Wagner K, Geiger MJ, Hirsch M, Schulze-Bonhage A, Klotz KA. Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy. *Epilepsy Behav* 2021;114:107558. DOI PubMed
  93. Berry-kravis E, Hagerman R, Budimirovic D, et al. A pivotal study of ZYN002 cannabidiol (CBD) transdermal gel in children and adolescents with fragile X syndrome [CONNECT-FX (ZYN2-CL-016)]. *Biol Psychiat* 2021;89:S226-7. DOI
  94. Johnson D, Hagerman R. Chapter 33-Medical use of cannabidiol in fragile X syndrome. Medicinal usage of cannabis and cannabinoids. Elsevier; 2023. pp. 415-26. DOI
  95. Berry-Kravis EM, Harnett MD, Reines SA, et al. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. *Nat Med* 2021;27:862-70. DOI
  96. Hessel D, Sansone SM, Berry-Kravis E, et al. The NIH toolbox cognitive battery for intellectual disabilities: three preliminary studies and future directions. *J Neurodev Disord* 2016;8:35. DOI PubMed PMC
  97. Lee HG, Imaichi S, Kraeutler E, et al. Site-specific R-loops induce CGG repeat contraction and fragile X gene reactivation. *Cell* 2023;186:2593-609.e18. DOI
  98. Derbis M, Kul E, Niewiadomska D, et al. Short antisense oligonucleotides alleviate the pleiotropic toxicity of RNA harboring expanded CGG repeats. *Nat Commun* 2021;12:1265. DOI PubMed PMC